Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

• Status: Active, not recruiting
• Trial end date: 2022-02-28
• Target enrollment: 0
• Participant gender: Male

Summary

This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify those patients with early neuroendocrine transdifferentiation and who are at greater risk for poor outcomes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University

Criteria

Inclusion Criteria:

• Patients with metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement

• Ability to lie still for PET scanning

• Patients must be able to provide written informed consent

Exclusion Criteria:

• Patients less than 18 years of age

• Patients without metastatic castration resistant prostate carcinoma with skeletal, visceral and/or nodal involvement

• Inability to lie still for PET scanning

• Patients unable to provide written informed consent